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OBJECTIVE: To evaluate the functional and histological effects of ganglioside G(M1) and erythropoietin after
experimental spinal cord contusion injury.
METHODS: Fifty male Wistar rats underwent experimental spinal cord lesioning using an NYU-Impactor device
and were randomly divided into the following groups, which received treatment intraperitoneally. The G(M1)
group received ganglioside G(M1) (30 mg/kg); the erythropoietin group received erythropoietin (1000 IU/kg);
the combined group received both drugs; and the saline group received saline (0.9%) as a control. A fifth group
was the laminectomy group, in which the animals were subjected to laminectomy alone, without spinal
lesioning or treatment. The animals were evaluated according to the Basso, Beattie and Bresnahan (BBB) scale,
motor evoked potential recordings and, after euthanasia, histological analysis of spinal cord tissue.
RESULTS: The erythropoietin group had higher BBB scores than the G(M1) group. The combined group had the
highest BBB scores, and the saline group had the lowest BBB scores. No significant difference in latency was
observed between the three groups that underwent spinal cord lesioning and intervention. However, the
combined group showed a significantly higher signal amplitude than the other treatment groups or the saline
group (po0.01). Histological tissue analysis showed no significant difference between the groups. Axonal index
was significantly enhanced in the combined group than any other intervention (po0.01).
CONCLUSION: G(M1) and erythropoietin exert therapeutic effects on axonal regeneration and electrophysiological
and motor functions in rats subjected to experimental spinal cord lesioning and administering these two
substances in combination potentiates their effects.
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’ INTRODUCTION
Ganglioside G(M1) is a therapeutic option for the treat-
ment of lesions of the central nervous system (CNS) (1). The
various properties attributed to G(M1) include the reduction
of neural edema by increasing the activities of sodium,
potassium and magnesium pumps; the homeostasis of
neural cells by reestablishing membrane equilibrium (2);
specifically increasing the levels of endogenous neurotrophic
factors, thus reducing the destruction of neurons following
trauma; inducing the plasticity mechanisms of injured spinal
circuits; and promoting the recovery of functional connec-
tions (3). Research involving G(M1) in humans has shown
that this treatment improved locomotor functions in victims
of spinomedullary trauma (4), but the interpretation of these
results is complicated because methylprednisolone had been
administered before G(M1) treatment (5).
Erythropoietin is a glycoprotein produced in the kidneys
of adults. This substance can mediate cytoprotection in
various tissues, including nervous tissue. Inhibition of
apoptosis, reduction of the inflammatory process, restoration
of vascular integrity and regeneration of neurons are the
primary activities attributed to this glycoprotein (6,7).
Erythropoietin stands out among the substances used in
neuroprotective therapy. In vivo, its neuroprotective proper-
ties have proven effective in studies using animal models ofDOI: 10.6061/clinics/2016(06)11
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ischemia, closed trauma, epilepsy and spinal lesioning. The
cellular and molecular mechanisms of this neuroprotective
agent remain uncertain (8). Erythropoietin also acts on
microglia, which are hematopoietic in origin, exhibit high
cell plasticity and play important roles in the immune system
and in the repair of the CNS (9).
This study was motivated by the possibility of the
synergetic use of G(M1) and erythropoietin as an adjuvant
treatment of spinal lesions based on a consistent line of
evidence from studies of experimental lesions in rats (10-15).
The use of these two substances together indicates a possible
breakthrough in the quality of neural regeneration, stem-
ming from the principle that minimal anatomical repairs of
the spinal cord can result in clinically significant improve-
ments in patients who experience spinal cord lesions.
Although the ability to walk may not be restored, axonal
regeneration, even if partial, may result in the recovery of
functions such as sphincter control, or upper limb function –
improvements that can translate to significant increases in
the autonomy of patients, who are often young.
’ OBJECTIVES
To evaluate the functional and histological effects of
treatment with monoganglioside G(M1) and erythropoietin
in spinal cord contusion lesions in Wistar rats.
’ METHODS
Design, ethics and animals
The research protocol for this experimental study involving
animals was evaluated and approved by the Research Ethics
Committee of our institution. The research laboratory strictly
adhered to all the international guidelines on handling and
pain control related to the care and use of animals in research.
Five animals were housed in each cage in the laboratory and
the animals were handled and induced to move prior to the
experiment so that they could become accustomed to the
researchers and to the experimental evaluation of motor
function after spinal cord injury. Ad libitum feeding and
hydration were maintained throughout the study.
Sixty male Wistar rats, aged 20 to 21 weeks and weighing
from 254 to 405 g, were used. All rats were weighed at the
beginning and the end of the study. All of the rats had
normal coats, normal clinical status and normal movement
capability at the beginning of the study. The sample size was
based on previous studies using 10 animals per group
(12,15). The experimental spinal cord lesion was confirmed
using the Basso, Beattie and Bresnahan (BBB) scale, indicat-
ing the lack of normal movement of the legs.
The following exclusion criteria were established: death
following experimental spinal cord lesioning, macroscopic
observation of abnormalities in the area of the spinal cord
lesion and autophagy or mutilation of the animals during the
observation period.
The rats were randomly divided into five groups of 12
animals per group:
 G(M1) group – rats undergoing experimental spinal cord
lesioning and receiving G(M1) ganglioside intraperitone-
ally (30 mg/kg);
 Erythropoietin group – rats undergoing experimental spinal
cord lesioning and receiving erythropoietin intraperitone-
ally (1000 UI/kg);
 Combined group – rats undergoing experimental spinal
cord lesioning and receiving both G(M1) (30 mg/kg) and
erythropoietin (1000 UI/kg) intraperitoneally;
 Saline group – rats undergoing experimental spinal cord
lesioning and receiving saline (0.9%) intraperitoneally
(control group);
 Laminectomy group – rats undergoing laminectomy alone,
without spinal cord lesioning and treatment.
Experimental spinal cord lesioning and
experimental interventions with G(M1)
and erythropoietin
In this study, all rats, even those not subjected to spinal
cord lesioning, underwent laminectomy under a surgical
microscope as a standardized procedure (11,14,15). Prior to
laminectomy, experimental spinal cord lesioning, motor
evoked potential (MEP) recording and euthanasia, the animals
were anesthetized via intraperitoneal injection of 10 mg/kg
xylazine and 50 mg/kg ketamine. The rats were examined to
confirm anesthesia as described elsewhere (14-16). A moderate
contusion lesion was produced at T10 using an NYU-Impactor
device as previously described (14,15); a 10-g impact rod was
released from a standardized height of 12.5 mm to compress
the spinal cord of all rats for 15 seconds.
The animals received preventative antibiotic therapy
(sodium cefazolin, 20 mg/kg, intraperitoneally) immediately
after the lesion and once a day for three days; this treatment
was extended to seven days in cases of persistent infection.
Signs of blood in the urine were considered to indicate an
untreatable urinary tract infection, prompting exclusion from
the study and euthanasia to prevent contamination of the
other animals.
Following spinal cord lesioning, pain control was achieved
by intramuscularly injecting 2 mg/kg meloxicam (once daily
for seven days) and tramadol chlorhydrate (5 mg/100 g,
once daily for seven days). The medications were adminis-
tered to the animals in all groups, including the control
group, for the same treatment duration.
Due to the loss of the micturition reflex as a result of the
spinal cord lesion, the bladder of the animals was manually
emptied twice daily until the animals regained bladder
function, which usually occurred on the third postoperative
day. The animals were observed for signs of infection,
dehydration, mutilation and autophagic behavior until the
42nd postoperative day, when they were sacrificed.
The study drugs were administered intraperitoneally at
the doses described above, always with the rats under
anesthesia and sedated. In the combined group, the injec-
tions were applied at different sites in the peritoneum using
different syringes.
Evaluation of locomotor function
The recovery of locomotor function was evaluated for 4 to
5 minutes using the BBB scale on days 2, 7, 14, 21, 28, 35 and
42 after spinal cord lesioning. Each rat was assessed
simultaneously by two suitably trained observers who had
no knowledge of the source group of the rats and were
blinded to their colleague’s evaluations, so as to avoid
interfering with each other’s results. When there was
disagreement between the evaluations, the lower score was
recorded for analysis.
The rats also underwent MEP recordings of the amplitude
and latency of the responses in the paws on both sides
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following transcranial electrical stimulation (13). MEP was
performed under anesthesia on the 42nd day after spinal
cord lesioning, the day of euthanasia. Muscular responses
were recorded by inserting pairs of monopolar needle
electrodes (sensor and reference electrodes) at a defined
and consistent inter-electrode distance into the proximal and
anterior musculature of the right and left hind limbs (13).
A monopolar needle electrode was placed in the lumbar
region as a ground. Transcranial electrical stimulation was
applied by inserting two corkscrew-type electrode needles
into the head of the rats along the inter-hemispheric line
in the frontal (anode) and occipital (cathode) lobes for
simultaneous bilateral stimulation. The device was calibrated
in accordance with the standards previously published by
our team and the transcranial electrical stimulation consisted
of a single stimulus of 0.2 ms in duration.
Euthanasia
At the end of the experimental period (after 42 days), all
the rats were euthanized according to the ethical guidelines
for animal experimentation. The euthanasia procedure was
performed in three steps: anesthesia (with ketamine and
xylazine), cardiac perfusion (for three minutes with a 0.2 M
phosphate buffer solution at pH 7.4 and 36oC, followed by a
4% paraformaldehyde buffer solution at pH 7.4, 100 ml/100 g)
and painless death (via intravenous injection of 5 ml of
potassium chlorate (at 19.1%)).
Necropsy and histological tissue analysis
After euthanasia, the presence of macroscopic abnormal-
ities, such as autophagic or mutilation lesions, was evaluated
in the autopsy. The lungs and the bladder were also
evaluated.
The spinal cord was examined and removed at the site of
the lesion, from T8 to T12 (approximately 2.5 cm in length).
The extracted segment was fixed and prepared for histolo-
gical analysis as described previously to detect the presence
of necrosis, hemorrhage, hyperemia, degeneration and
infiltrates (12).
Two representative 2-mm-thick sections from each spinal
cord specimen, 1 mm distal and 1 mm proximal to the center
of the lesion, were selected, fixed in osmium tetroxide
solution (2%) and stained with toluidine blue (1%) for axonal
counting (12,15).
Photographs at 40 x magnification were analyzed using
SigmaScan Pro 5.0 software. Neurons with a diameter equal
to or greater than 15 mm were counted (17). The following
formula was used to calculate the regeneration index (RI):
RI = (number of axons in the distal area/number of axons
in the proximal area) x 100 (18).
A single experienced pathologist who was blinded to the
rat allocation performed the analyses.
Statistical analysis
The primary outcome evaluated in this study was the BBB
score on the 42nd postoperative day. Histological evaluation
variables and MEP results were considered as secondary
outcomes.
Data were expressed as means and standard deviations
and were tested for normality using the Kolmogorov-
Smirnov test. When the data presented a normal distribution,
they were evaluated using parametric tests.
Student’s t test for paired samples was used to compare
the right and left sides. One-way analysis of variance
(ANOVA) was used to compare the five groups. The chi
square test was only used for the axon counting results.
Bonferroni correction was used for post hoc multiple
comparison testing. The Kruskal-Wallis test was used for
the analysis of the BBB scores between groups. For the
comparison of the results between weeks in a given group,
the Friedman test was used because the data were not
normally distributed (po0.05).
We started with a null hypothesis, considering a prob-
ability of type I error of 5%. The Statistical Package for the
Social Sciences (SPSS), version 19.0 for Windows, was used
in the analysis.
’ RESULTS
The five groups of rats underwent the planned interven-
tions without technical complications. Two rats from each
group were excluded because of autophagic behavior and
infection. Weight gain occurred in the G(M1), combined and
saline groups (averages of 6.6 g, 5.9 g and 50.3 g, respectively),
but slight weight loss occurred in the erythropoietin and
laminectomy groups (6.8 g and 23.1 g, respectively). Con-
sidering that the initial mean weight of the rats was 346.52 g,
the average total weight gain was 6.58 g.
Functional analysis: Locomotion
The evaluation of motor function using the BBB scale,
conducted at seven different time points, showed no
difference between the right and left sides of the rats
(p40.1). Thus, for the comparison between groups, the data
for the right and left sides were combined. The evolution of
the BBB scores is shown in Figure 1. All groups exhibited
increasing BBB scores over time and these increases were
statistically significant beginning from the second week of
analysis (po0.05).
On the first evaluation, conducted two days after the
trauma and intervention, no statistically significant differ-
ence in locomotion between the groups subjected to
trauma was observed (p40.05). Only the laminectomy
group (which was not subjected to spinal cord lesioning)
showed a difference in locomotion compared to the saline
group and the intervention groups (po0.05). Beginning
with the second evaluation, performed one week after
spinal cord lesioning (or laminectomy), the groups began
to show statistically significant differences in locomotion
(po0.05). In this second evaluation, the erythropoietin
group exhibited significantly higher BBB scores than the G
(M1) group (p=0.002). Moreover, the combined (G(M1) and
erythropoietin) group exhibited significantly higher BBB
scores than all other groups subjected to spinal cord
lesioning (po0.05). The saline group exhibited the lowest
BBB scores at all time points examined (po0.05) and the
laminectomy group exhibited higher BBB scores than the
other groups at all time points (po0.05).
Functional evaluation via motor evoked
potential recording
The MEP recordings provided data for the signal latency
and amplitude on both sides of the examined rats.
No statistically significant difference in either latency or
amplitude was found between the two sides (p40.05).
Thus, comparison between the groups was performed
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on the pooled data of the right and left sides of the rats
in each group. The detailed results are presented in Tables 1
and 2.
The latency of the lower limbs showed a statistically
significant difference (po0.01) between the groups. The
Bonferroni post hoc multiple comparison test showed that
the latency was higher in the saline group and was
significantly lower in the laminectomy group (po0.05) than
in the other groups. The comparison between the three
intervention groups did not show a statistically significant
difference in latency (p40.05), as shown in Figure 2.
The signal amplitude of the lower limbs was significantly
different between the groups (po0.01). Based on the
Bonferroni post hoc multiple comparison test, the laminect-
omy group showed the greatest amplitude and the saline
group exhibited a lower amplitude than the three
intervention groups; these differences compared to the G
(M1), erythropoietin and combined groups were statistically
significant (po0.05). Additionally, the combined group exhib-
ited a statistically significant difference in amplitude compared
with all other groups (po0.01), as shown in Figure 3.
Histological analysis
Histological evaluation of the tissue in the area of the
spinal cord lesion confirmed the presence of necrosis
(Table 3), hemorrhage (Table 4), hyperemia (Table 5), degen-
eration of the substance (Table 6) and cellular infiltration
(Table 7) in the 50 examined rats. The laminectomy group,
which was not subjected to spinal cord lesioning, did not
exhibit degeneration, hyperemia, hemorrhage, or necrosis.
The differences in the histological scores between the groups
was not statistically significant (p40.05).
Figure 1 - BBB scores over time.
Table 1 - Motor evoked potential results: latency in the lower limbs in each group.
Mean SD SE 95% CI Minimum Maximum
IL SL
G(M1) 8.2000 1.69395 0.37878 7.4072 8.9928 4.50 12.50
ERI 6.9400 1.73278 0.38746 6.1290 7.7510 3.50 10.00
COMB 7.0900 1.47609 0.33006 6.3992 7.7808 4.10 10.20
SS 9.7850 2.39611 0.53579 8.6636 10.9064 6.30 16.30
LAM 4.2400 0.87503 0.19566 3.8305 4.6495 2.60 6.10
Total 7.2510 2.47576 0.24758 6.7598 7.7422 2.60 16.30
G(M1) = ganglioside G(M1); ERI = erythropoietin; COMB = combination of ganglioside G(M1) and erythropoietin; SS = saline solution; LAM = laminectomy;
95% CI = 95% confidence interval; SD = standard deviation; SE = standard error; IL = inferior limit; SL = superior limit.
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The Kruskal-Wallis test showed a significant difference in
the axonal RI between the groups when considered together
(po0.01), as shown in Figure 4. As demonstrated in the
figure, the saline group clearly exhibited a lower RI than the
combination group. The Mann-Whitney test, which was
performed for a pairwise comparison of the groups, showed
that combined treatment with G(M1) and erythropoietin
resulted in a significantly higher RI than any other
intervention (po0.01).
’ DISCUSSION
In recent years, research on the topic of spinal cord lesions
has shifted its focus from attempting to interrupt or delay the
chain of events that results in secondary lesion formation to
identifying drugs that effectively promote neuronal repair
and regeneration (19). Because nervous system lesions recover
slowly and incompletely (20), the current research encom-
passes a variety of strategies focused on reducing secondary
damage and stimulating regeneration. These strategies range
from physiotherapy (e.g., exercise, hypothermia and oxy-
gen therapy), aided by the administration of compounds
that may increase perfusion and stimulate angiogenic
responses, to cellular therapies and forms of therapy. The
outcomes of the current treatment strategies can vary
depending on the species of the mammalian model used in
the laboratory (10-12,14,15,21-24).
Ganglioside G(M1) and methylprednisolone comprise the
only currently available compounds for the prevention of
secondary spinal cord lesions in humans (25). Theoretically,
Table 2 - Motor evoked potential results: amplitude in the lower limbs in each group.
Mean SD SE 95% CI Minimum Maximum
IL SL
G(M1) 235.2500 92.03082 20.57872 192.1783 278.3217 122.00 425.00
ERI 393.4000 201.76312 45.11561 298.9720 487.8280 215.00 854.00
COMB 1110.5500 178.84644 39.99128 1026.8473 1194.2527 785.00 1452.00
SS 422.8000 164.70247 36.82859 345.7169 499.8831 152.00 699.00
LAM 3772.8500 452.91015 101.27379 3560.8815 3984.8185 2895.00 4521.00
Total 1186.9700 1356.60324 135.66032 917.7905 1456.1495 122.00 4521.00
G(M1) = ganglioside G(M1); ERI = erythropoietin; COMB = combination of ganglioside G(M1) and erythropoietin; SS = saline solution; LAM =
laminectomy; 95% CI = 95% confidence interval; SD = standard deviation; SE = standard error; IL = inferior limit; SL = superior limit.
Figure 2 - Latency, as evaluated by motor evoked potential recording, in the lower limbs of Wistar rats subjected to experimental spinal
cord contusion lesioning and of control rats not undergoing experimental lesioning.
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in promoting regeneration, G(M1) would be considered as a
‘‘pro-inflammatory’’ factor, which in many cases would not
be administered at the time of acute trauma. However, the
goal of methylprednisolone administration is to reduce local
inflammation and lipid peroxidation, opposing the activities
of G(M1).
Erythropoietin, acting as a neuroprotective agent, is a
component of the preventative treatment of ischemia-induced
axonal death. The primary contribution of our study is the
finding of the potentiating effects of combined treatment with
erythropoietin and G(M1), i.e., a significant enhancement of
axonal regeneration due to the combined administration of
these two drugs. To our knowledge, these compounds have
not yet been tested together.
In our study, beyond the first week after spinal cord
lesioning, the locomotor function (measured by the BBB scale)
Figure 3 - Amplitude, as evaluated by motor evoked potential recording, in the lower limbs of Wistar rats subjected to experimental
spinal cord contusion lesioning and of control rats not undergoing experimental lesioning.
Table 3 - Necrosis in the distal section of the spinal cord in Wistar rats subjected to experimental spinal cord contusion lesioning.
Group
Necrosis G(M1) ERI Combined Saline Laminectomy Total
Absent Count 2 3 4 2 10 21
% Necrosis 9.5% 14.3% 19.0% 9.5% 47.6% 100.0%
% Group 20.0% 30.0% 40.0% 20.0% 100.0% 42.0%
Mild Count 2 4 4 3 0 13
% Necrosis 15.4% 30.8% 30.8% 23.1% 0.0% 100.0%
% Group 20.0% 40.0% 40.0% 30.0% 0.0% 26.0%
Moderate Count 5 2 2 3 0 12
% Necrosis 41.7% 16.7% 16.7% 25.0% 0.0% 100.0%
% Group 50.0% 20.0% 20.0% 30.0% 0.0% 24.0%
Intense Count 1 1 0 2 0 4
% Necrosis 25.0% 25.0% 0.0% 50.0% 0.0% 100.0%
% Group 10.0% 10.0% 0.0% 20.0% 0.0% 8.0%
Total Count 10 10 10 10 10 50
% Necrosis 20.0% 20.0% 20.0% 20.0% 20.0% 100.0%
% Group 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
G(M1) = ganglioside G(M1); ERI = erythropoietin.
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of the animals that received erythropoietin was significantly
greater than that of the rats that received G(M1). However, the
group of rats that received the combined treatment exhibited
greater locomotor function than all other groups subjected to
spinal cord lesioning. The evidence that locomotor function
continued to improve until the sixth week, especially in the
group that received both G(M1) and erythropoietin, suggests
that these two drugs may be effective in the long term rather
than the short term.
MEPs are electrical responses of the peripheral neuromus-
cular pathways to stimulation of the motor cortex. MEP
recording serves as an assessment of electrical conduction
along the neural pathways; therefore, the results of this
method can indicate a spinal cord lesion (21,26). In this test,
two variables were assessed: signal latency and amplitude.
Latency refers to the time required for an electrical impulse
to leave the rat’s skull and reach its limbs. Rats are very
small animals and the latency of any individual in a cohort
is always very similar to that of the others. Additionally,
any functioning nerve fiber is sufficient to carry the signal
from one point to another and the impulse is recorded
regardless of the number of existing fibers. For this reason,
we do not consider the signal latency to be very useful in
experimental studies of rats and this limitation could even
lead to questioning whether to perform MEP recording
in rats - except for the purpose of measuring the signal
amplitude.
The signal amplitude, another parameter measured in
MEP recordings, is more useful than the signal latency
because the amplitude is related to the quantity of axons
present that carry an electrical impulse. A spinal cord
containing more axons produces a higher signal amplitude.
For this reason, the groups with greater functional perfor-
mance in this study also exhibited higher signal amplitudes
than the groups with lower functional performance. The
MEP signals are also used to confirm spinal cord lesioning in
experimental studies; a decrease of 80% or more in the signal
amplitude confirms the presence of a lesion (27-29). New
methods are being developed to improve the accuracy of
MEP recording for use specifically in rats (26,30) and to
compare the effects of various anesthetics, which certainly
influence the MEP recording results (30).
The signal amplitude and the BBB scores observed in this
study were higher in the rats that received combined
Table 4 - Hemorrhage in the distal section of the spinal cord in Wistar rats subjected to experimental spinal cord contusion lesioning.
Group
Hemorrhage G(M1) ERI Combined Saline Laminectomy Total
Absent Count 1 4 4 3 10 22
% Necrosis 4.5% 18.2% 18.2% 13.6% 45.5% 100.0%
% Group 11.1% 40.0% 40.0% 30.0% 100.0% 44.9%
Mild Count 3 3 4 4 0 14
% Necrosis 21.4% 21.4% 28.6% 28.6% 0.0% 100.0%
% Group 33.3% 30.0% 40.0% 40.0% 0.0% 28.6%
Moderate Count 2 3 1 2 0 8
% Necrosis 25.0% 37.5% 12.5% 25.0% 0.0% 100.0%
% Group 22.2% 30.0% 10.0% 20.0% 0.0% 16.3%
Intense Count 3 0 1 1 0 5
% Necrosis 60.0% 0.0% 20.0% 20.0% 0.0% 100.0%
% Group 33.3% 0.0% 10.0% 10.0% 0.0% 10.2%
Total Count 9 10 10 10 10 49
% Necrosis 18.4% 20.4% 20.4% 20.4% 20.4% 100.0%
% Group 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
G(M1) = ganglioside G(M1); ERI = erythropoietin.
Table 5 - Hyperemia in the distal section of the spinal cord in Wistar rats subjected to experimental spinal cord contusion lesioning.
Group
Hyperemia G(M1) ERI Combined Saline Laminectomy Total
Absent Count 2 4 5 2 10 23
% Necrosis 8.7% 17.4% 21.7% 8.7% 43.5% 100.0%
% Group 20.0% 40.0% 50.0% 20.0% 100.0% 46.0%
Mild Count 4 5 4 4 0 17
% Necrosis 23.5% 29.4% 23.5% 23.5% 0.0% 100.0%
% Group 40.0% 50.0% 40.0% 40.0% 0.0% 34.0%
Moderate Count 1 1 1 3 0 5
% Necrosis 20.0% 20.0% 20.0% 40.0% 0.0% 100.0%
% Group 10.0% 10.0% 10.0% 20.0% 0.0% 10.0%
Intense Count 3 0 0 2 0 5
% Necrosis 60.0% 0.0% 0.0% 40.0% 0.0% 100.0%
% Group 30.0% 0.0% 0.0% 20.0% 0.0% 10.0%
Total Count 10 10 10 10 10 50
% Necrosis 20.0% 20.0% 20.0% 20.0% 20.0% 100.0%
% Group 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
G(M1) = ganglioside G(M1); ERI = erythropoietin.
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treatment with erythropoietin and G(M1). Although we
demonstrated significant differences in locomotion capacity
among the rats treated with the combined therapy, our
results did not demonstrate a recovery at the tissue level.
Histological analysis was performed on tissues stained with
hematoxylin and eosin and observed under an optical
microscope due to the availability of these materials.
However, in both the international literature and in our
laboratory experience, this technique has been shown to be
deficient in terms of differentiating between specimens. The
analysis of histological sections was conducted quantita-
tively to enable statistical analysis. However, this quantifica-
tion is subjective with respect to the examined variables. We
believe that if the identical analysis were performed by an
additional observer or using an electron microscope, we may
have obtained the same results from the histological analysis
as the results of the functional tests in rats in vivo. However,
analysis of toluidine blue-stained axons at a higher magni-
fication showed that the rate of regeneration in our
experimental model, based on the number and diameter of
axons detected in the spinal cord tissue, was higher in the
rats treated with both G(M1) and erythropoietin than in the
rats treated with either agent alone.
The devastating nature of spinal cord lesions in humans
continues to prompt thousands of studies each year and this
phenomenon makes it difficult to keep track of the most
promising proposals. The cascade of secondary events follow-
ing a primary mechanical lesion, in addition to its initial
necrotic properties, involves an apoptotic mechanism that has
prompted investigations at the cellular level. These secondary
events include vascular, ischemic, and homeostatic abnormal-
ities, as well as oxidative stress and inflammatory responses.
Thus, new treatment options in addition to ganglioside and
methylprednisolone are needed for this injury.
We believe that there is a tendency towards increasingly
multifactorial therapy for spinal cord lesions using multiple
concomitant approaches and, in the case of medications,
involving combined treatment with several drugs that poten-
tiate the effects of one another. The neuroprotective effects
of various compounds are currently being investigated (25).
Specifically, erythropoietin and G(M1) continue to be
investigated, and sodium and calcium channel blockers,
minocycline, corticosteroids, progesterone, aminosteroids,
opioid receptor antagonists, serotonin antagonists, thyrotropin-
releasing hormone, antioxidants, free radical scavengers,
growth factors, neurotrophic factors, paclitaxel, clenbuterol,
Table 6 - Axonal degeneration in the distal section of the spinal cord in Wistar rats subjected to experimental spinal cord contusion
lesioning.
Group
Degeneration G(M1) ERI Combined Saline Laminectomy Total
Absent Count 2 3 3 0 10 18
% Necrosis 11.1% 16.7% 16.7% 0.0% 55.6% 100.0%
% Group 20.0% 30.0% 30.0% 0.0% 100.0% 36.0%
Mild Count 4 6 6 6 0 22
% Necrosis 18.2% 27.3% 27.3% 27.3% 0.0% 100.0%
% Group 40.0% 60.0% 60.0% 60.0% 0.0% 44.0%
Moderate Count 3 1 1 3 0 8
% Necrosis 37.5% 12.5% 12.5% 37.5% 0.0% 100.0%
% Group 30.0% 10.0% 10.0% 30.0% 0.0% 16.0%
Intense Count 1 0 0 1 0 2
% Necrosis 50.0% 0.0% 0.0% 50.0% 0.0% 100.0%
% Group 10.0% 0.0% 0.0% 10.0% 0.0% 4.0%
Total Count 10 10 10 10 10 50
% Necrosis 20.0% 20.0% 20.0% 20.0% 20.0% 100.0%
% Group 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
G(M1) = ganglioside G(M1); ERI = erythropoietin.
Table 7 - Cellular infiltration into the distal section of the spinal cord in Wistar rats subjected to experimental spinal cord contusion
lesioning.
Group
Infiltration G(M1) ERI Combined Saline Laminectomy Total
Absent Count 4 5 6 2 8 25
% Necrosis 16.0% 20.0% 24.0% 8.0% 32.0% 100.0%
% Group 40.0% 50.0% 60.0% 20.0% 80.0% 50.0%
Mild Count 3 3 4 5 2 17
% Necrosis 17.6% 17.6% 23.5% 29.4% 11.8% 100.0%
% Group 30.0% 30.0% 40.0% 50.0% 20.0% 34.0%
Moderate Count 3 2 0 3 0 8
% Necrosis 37.5% 25.0% 0.0% 37.5% 0.0% 100.0%
% Group 30.0% 20.0% 0.0% 30.0% 0.0% 16.0%
Intense Count 10 10 10 10 10 50
% Necrosis 20.0% 20.0% 20.0% 20.0% 20.0% 100.0%
% Group 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
G(M1) = ganglioside G(M1); ERI = erythropoietin.
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gabexate mesylate, activated protein C, caspase inhibitors,
tacrolimus, the copolymer polyethylene glycol (PEG) (11,25)
and neurotrophins (23) have been examined. The expression of
genes following spinomedullary trauma (22) and stem cell
transplantation (21), which we have already begun to explore
in our laboratory, may be promising paths of research.
In light of the above findings, it is clear to us that a ‘‘cure’’
for spinomedullary trauma will be complex and unfortu-
nately will not be accomplished by a single form of therapy.
In addition to pharmacological treatment, physical and
biological therapies, or even the use of robotics as a
component of treatment, should be included the treatment
approach. Unfortunately and contrary to the very optimistic
forecasts that expected a cure for spinomedullary trauma
by the end of the ‘‘Decade of the Spine’’ (2001 to 2010),
it has become increasingly clear that a definitive solution
for this problem remains a long way off. Collaborative,
multidisciplinary studies, such as the one presented in this
report, form the building blocks that will help to develop a
definitive ‘‘cure’’ for spinomedullary trauma.
This study showed that G(M1) and erythropoietin exert
therapeutic effects on motor and electrophysiological func-
tion and on axonal regeneration in Wistar rats subjected to
experimental spinal cord lesioning. Moreover, combined
treatment with these two agents potentiates their effects.
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